Who holds Heat Biologics'stock?
Apr 20, 2022 · Heat Biologics (NASDAQ:HTBX) Stock Passes Below 200-Day Moving Average of $3.87 americanbankingnews.com - April 9 at 3:02 AM: Heat Biologics, Inc. (NASDAQ:HTBX) Short Interest Update americanbankingnews.com - April 1 at 3:12 PM: Heat Biologics (NASDAQ:HTBX) Shares Cross Above 50-Day Moving Average of $2.66 americanbankingnews.com - March 26 …
What do investors need to know about Heat Biologics’ reverse stock split?
Apr 03, 2022 · Heat Biologics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 728,600 shares, a drop of 18.3% from the February 28th total of 891,400 shares. Based on an average daily volume of 207,300 shares, the short-interest ratio is presently 3.5 days. Currently, 3.0% of the company's stock are short sold.
Why is Heat Biologics (HTBX) stock heating up?
Find the latest Heat Biologics, Inc. (HTBX) stock quote, history, news and other vital information to help you with your stock trading and investing.
What is the upside for Heat Biologics'stock?
Aug 10, 2020 · One of the reasons for the fall is competition coming from Vaxart, which has a financial arms chest . Update 2: Heat Biologics' equity failed to live up to early trading prospects and changes hands...
What happened to Heat Biologics?
Heat expects to commence trading as an NYSE American-listed company when markets open on Monday, February 14, 2022. The Company's common stock will continue to trade under its existing “HTBX” symbol. The Company will continue to trade on the Nasdaq Capital Market until the close of market on Friday, February 11, 2022.Feb 2, 2022
Is Heat Biologics a good investment?
The Heat Biologics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Will Heat Biologics stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Heat Biologics Inc have a median target of 11.00, with a high estimate of 15.50 and a low estimate of 8.00. The median estimate represents a +341.77% increase from the last price of 2.49.
Is Heat Biologics a good company?
While Heat Biologics seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity.Jan 4, 2022
Is Heat Biologics a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last twelve months. There are currently 3 buy rating...
How has Heat Biologics' stock been impacted by Coronavirus?
Heat Biologics' stock was trading at $4.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization....
Are investors shorting Heat Biologics?
Heat Biologics saw a decline in short interest in February. As of February 28th, there was short interest totaling 891,400 shares, a decline of 15....
How were Heat Biologics' earnings last quarter?
Heat Biologics, Inc. (NASDAQ:HTBX) posted its quarterly earnings results on Friday, March, 11th. The biopharmaceutical company reported ($0.54) EPS...
When did Heat Biologics' stock split? How did Heat Biologics' stock split work?
Heat Biologics shares reverse split before market open on Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10t...
What price target have analysts set for HTBX?
3 brokers have issued 12 month price targets for Heat Biologics' stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate He...
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the following people: Mr. Jeffrey Alan Wolf , Founder, Chairman, CEO & Pres (Age 58, Pay $1.16M) Mr. Wi...
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include Verastem (VSTM) , Ovid Therapeutics (OVID) , Immutep (IMMP) , Adagene (ADAG) , CymaB...
What other stocks do shareholders of Heat Biologics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics...
Is Heat Biologics a buy right now?
What stocks does MarketBeat like better than Heat Biologics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heat Biologics stock.#N#View analyst ratings for Heat Biologics or view top-rated stocks.
When is Heat Biologics' next earnings date?
Wall Street analysts have given Heat Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Heat Biologics wasn't one of them.
How were Heat Biologics' earnings last quarter?
Heat Biologics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for Heat Biologics.
How has Heat Biologics' stock price been impacted by COVID-19?
Heat Biologics, Inc. (NASDAQ:HTBX) announced its earnings results on Tuesday, August, 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.05.
When did Heat Biologics' stock split? How did Heat Biologics' stock split work?
Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HTBX shares have increased by 797.1% and is now trading at $6.28.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for HTBX?
Shares of Heat Biologics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018.
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
4 brokerages have issued twelve-month target prices for Heat Biologics' shares. Their forecasts range from $14.00 to $22.00. On average, they expect Heat Biologics' share price to reach $19.00 in the next twelve months.
HTBX: September Business Update
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C.
Heat Biologics to Provide Corporate Update
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Business Update Conference Call Heat Biologics, Inc. (NASDAQ:HTBX) hosted a business update conference call on September 2, 2021 to discuss the status of active programs, objectives of new subsidiaries, and longer term opportunities for the company.
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
Conference call scheduled for September 2nd at 11:00 AM ETDURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc.
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
Developing a new era of precision medicines using a unique and proprietary drug discovery platformDURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc.
Heat Biologics Announces New Additions to Biothreat Advisory Board
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the addition of Mark Pryor, former US Senator from the State of Arkansas, to the Company’s Biothreat Advisory Board.
Heat Biologics Announces Formation of Biothreat Advisory Board
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc.
HTBX Stock Forecast
Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, David Lasseter, and Former US Representative Jack Kingston, join newly formed BoardDURHAM, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc.
Why is PLTR stock up?
Heat Biologics’ stock price nearly fell below $2.00 per share on Friday, which seems to be a psychological barrier that investors are unwilling to accept. The stock had already dipped below that level once earlier this week but quickly returned back over that threshold.
What is the most important factor in valuation?
What we really like to see is when a trend does what it wants to do and ignores the underlying newsflow. Palantir did exactly this on Thursday as the stock rallied by over 2% and shrugged off the negative news story from the New York Post.
Is Heat Biologics stock overvalued?
Growth is probably one of the most important factors in the valuation of a company. GuruFocus' research has found that growth is closely correlated with the long-term performance of a company's stock. If a company's business is growing, the company usually creates value for its shareholders, especially if the growth is profitable. Likewise, if a company's revenue and earnings are declining, the value of the company will decrease. Heat Biologics's 3-year average revenue growth rate is worse than 85% of the companies in Biotechnology industry. Heat Biologics's 3-year average EBITDA growth rate is 59.7%, which ranks better than 93% of the companies in Biotechnology industry.
A pre-print is sending the biotech's shares higher today
Heat Biologics Stock Appears To Be Significantly Overvalued. Because Heat Biologics is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth.
What happened
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
So what
Shares of the developmental biotech Heat Biologics ( NASDAQ:HTBX) jumped by as much as 21% in pre-market trading Wednesday morning. The company's shares perked up in response to the release of a pre-print (a preliminary article that has yet to be peer-reviewed) discussing the animal data for its COVID-19 vaccine candidate.
Now what
Although Heat won't have a vaccine ready for public consumption anytime soon, its vaccine candidate may end up playing a critical role in halting the ongoing pandemic. The key issue is that Heat's vaccine is designed to ramp up T-cell immunity -- not simply antibodies.